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Molecular mimicry between Campylobacter jejuni lipo-oligosaccharides (LOSs) and human
gangliosides GM1 and GD1a induces the production of anti-GM1 and anti-GD1a antibodies,
and the development of Guillain-Barré syndrome. Complexes of two different gangliosides
form new molecular shapes capable of enhancing recognition by anti-ganglioside antibod-
ies. To test the hypothesis that the complex of GM1-like and GD1a-like LOSs of C. jejuni in-
duces the development of anti-GM1b antibodies in Guillain-Barré syndrome patients.
Methods
Mass spectrometry analysis determined the LOS outer core structures, with which mice
were immunized. IgG antibodies to single gangliosides and complex of gangliosides
were tested in sera from Guillain-Barré syndrome patients from whom C. jejuni LOS had
been isolated.
Results
Two isolates from GBS patients who had anti-GM1b antibodies, but neither anti-GM1 nor
-GD1a antibodies, expressed both GM1-like and GD1a-like LOSs, but not GM1b-like LOS.
Anti-GM1b antibodies were induced in one of the mice immunized with the C. jejuni bearing
GM1-like and GD1a-like LOS. Sera from 20 patients had antibodies to the complex of GM1
and GD1a, all of which carried anti-GM1b reactivity. Five of these sera harbored neither
anti-GM1 nor anti-GD1a antibodies. IgG antibodies to the complex were absorbed by
GM1b, but by neither GM1 nor GD1a.
Conclusions
GM1-like and GD1a-like LOSs form a GM1b epitope, inducing the development of anti-
GM1b antibodies in patients with Guillain-Barré syndrome subsequent to C. jejuni enteritis.
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Here, we present a new paradigm that the complex of two different structures forms a new
molecular mimicry, inducing the production of autoantibodies.
Introduction
Molecular mimicry between Campylobacter jejuni lipo-oligosaccharides (LOSs) and human
gangliosides GM1 and GD1a induces the production of anti-GM1 and anti-GD1a IgG antibod-
ies, and the development of axonal Guillain-Barré syndrome (GBS) [1, 2]. GM1b is a compo-
nent of human peripheral nerves, and anti-GM1b IgG antibodies are also associated with
axonal GBS, subsequent to C. jejuni enteritis [3, 4]. Some patients with GBS have no antibodies
to single gangliosides, but have antibodies to heteromeric complexes of two different ganglio-
sides when mixed in 1:1 molar ratio [5]. Heteromeric complexes are defined as structurally dis-
tinct gangliosides that interact to form new molecular shapes capable of enhancing recognition
by anti-ganglioside antibodies [6]. A combinatorial glycoarray methodology was recently used
to assess the frequency of glycolipid complex antibodies in a cohort of GBS patients [7]. The in-
clusion of glycolipid complexes increased the positivity rate of the sera from patients with the
demyelinating form of GBS and antibodies against specific complexes were found to be associ-
ated with particular clinical features.[1]Infection by C. jejuni bearing two different ganglioside-
like LOSs may induce the production of antibodies against ganglioside complexes [8].
To identify the mechanism by which the anti-GM1b antibodies are induced, we analyzed
the LOS outer core structure of C. jejuni strains isolated from GBS patients who had anti-
GM1b antibodies. Unexpectedly, however, we found that the isolates expressed GM1 and
GD1a mimics, but not GM1b mimic (Fig 1A). In the current study, we tested a working hy-
pothesis that a complex of GM1-like and GD1a-like LOSs forms a new epitope, inducing the
development of anti-GM1b antibodies.
Methods
Serum samples and C. jejuni strains
Sera were available from 119 of 138 patients with C. jejuni-isolated GBS and related conditions
at the acute phase [9]. Written informed consent was obtained from all the patients, and the
Ethical Committee of Dokkyo Medical University, Japan, approved the performance of this
study. LOS biosynthesis locus and cstII genotype (Thr/Asn51) were determined by PCR screen-
ing of specific genes and by sequencing of the cstII gene as previously described [9, 10].
Mass spectrometry analysis
C. jejuni was grown overnight on a single agar plate and the cells were treated with proteinase
K, RNAse A and DNAse I as previously described [10]. The digested cells were treated with hy-
drazine to cleave O-linked fatty acids and the O-deacylated LOS samples were analyzed by cap-
illary electrophoresis coupled to electrospray ionization mass spectrometry [11].
Mice immunization
Mice lacking the functional gene for (N-acetylneuraminyl)-galactosylglucosylceramide N-acet-
ylgalactosaminyltransferase are immune naive hosts against gangliosides, and show a strong
IgG response to GM1-like and GD1a-like LOSs [12]. A C. jejuni strain (GC105) isolated from
a patient with GBS carries both GM1-like and GD1a-like LOSs as described below, whereas
Campylobacter LOS Complex in GBS
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genome strain NCTC11168 bears GM1-like and GM2-like LOSs, but no GD1a-like LOS [13].
The mice were immunized intraperitoneally 5 times at 2-week intervals with 1 mg (dry weight)
of heat-killed lysate of C. jejuni [14]. This research was approved by the Animal Care and Use
Committee, Dokkyo Medical University, Japan (approval no. 00–22). The mice were treated
according to the Guidelines for the Care and Use of Laboratory Animals, Dokkyo Medical Uni-
versity, Japan.
Enzyme-linked immunosorbent assay
IgG antibodies to individual gangliosides (GM1, GM1b, GM2, GD1a, GalNAc-GD1a, GD1b,
GD2, GT1a, GT1b or GQ1b; 10 pmol/well) were measured in sera (starting at 1:500 dilution)
from the patients and mice using peroxidase-conjugated anti-human or anti-mouse IgG anti-
bodies [15]. IgG antibodies to ganglioside complex GM1/GD1a (cM1/D1a) were tested with a
mixture of GM1 and GD1a (each 5 pmol/well) as antigen. Anti-cM1/D1a antibodies were
judged positive when the optical density of the antibodies was 0.5 greater than the sum of opti-
cal densities of antibodies to individual GM1 and GD1a [16]. IgG antibodies to other ganglio-
side complexes were measured as well. Frequency differences between the groups were
compared by means of Fisher’s exact test using SPSS 12.0J software (SPSS Inc., Chicago, IL). A
difference was considered significant when the two-sided p value was less than 0.05. Absorp-
tion studies were performed as described elsewhere [17]. Absorption rates (%) were calculated
Fig 1. GM1-like and GD1a-like lipo-oligosccharides (LOSs). (A) Schematic structures of GM1, GD1a and GM1b gangliosides, as well as GM1-like and
GD1a-like LOSs of Campylobacter jejuni. (B) Proposed LOS outer core structure of C. jejuni strains (GC016 and GC105) isolated from patients with GBS
who had anti-GM1b antibodies, but neither anti-GM1 nor anti-GD1a antibodies. Gal = Galactose; NeuAc = N-Acetylneuraminic acid; GalNAc = N-
Acetylgalactosamine; Hep = L-glycero-D-manno-Heptose; Glc = Glucose; Kdo = 3-deoxy-D-manno-2-Octulosonic acid; PEtn = Phosphoethanolamine. (C)
C. jejuni (GC016) LOS with and without neuraminidase treatment. Anti-GD1a monoclonal antibody reactivity to the LOS was decreased after the treatment,
whereas anti-GM1 monoclonal antibody reactivity was increased. This indicates that the neuraminidase-treatment transformed GD1a-like LOS into GM1-like
LOS by removing the terminal neuraminic acid. (D) Absorption studies using antibodies against cM1/D1a with various antigens. Anti-cM1/D1a IgG antibodies
from the serum of a patient with GBS (S382) were absorbed by the intact GC016 LOS (black bar; GM1/GD1a mimics) and a mixture of GM1 and GD1a
gangliosides (gray bar), but not by neuraminidase-treated GC016 LOS (GM1mimic as shown in A) and NCTC11168 LOS (GM1/GM2mimics).
doi:10.1371/journal.pone.0124004.g001
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from [1−(optical densities in wells with serum with absorption-treatment) / (optical densities
in reference wells with serum without absorption-treatment)] x 100.
Crude LOS fractions were prepared from C. jejuni strains, and the presence of GM1-like,
GD1a-like, GM1/GD1a-like or GM1b-like LOS was determined using monoclonal antibodies
[anti-GM1 (GB2) and anti-GD1a (GB1)], cM1/D1a serum (S382) or GM1b-specific serum
(S8056) from patients with GBS as described elsewhere [18]. GD1a-like LOS was treated over-
night with the neuraminidase from Arthrobacter ureafaciens (Nakalai Tesque, Inc., Kyoto,
Japan) at a concentration of 0.3 mU/ml acetate buffer (pH 5.0) at 37°C. This treatment in the
absence of surfactant is expected to cleave only the terminal sialic acid in the ganglioside.
Thin-layer chromatography with immunostaining
Bovine brain ganglioside mixture, authentic GM1b and a mixture of GM1 and GD1a were spot-
ted on a thin-layer chromatography plate and developed with chloroform/methanol/12 mM
magnesium chloride in water (5:4:1, by volume) [19]. After the development, a mixture of GM1
and GD1a was spotted on a different lane. Each plate was overlaid with serum (1:50 dilution,)
from Patient 4 in Table 1, followed by peroxidase-conjugated anti-human IgG antibodies.
Results
Structural characterization of C. jejuni LOSs from patients with GBS
associated with anti-GM1b antibodies
Patients 1 to 5 with GBS harbored the anti-GM1b antibodies, but neither anti-GM1 nor anti-
GD1a antibodies (Table 1). All the 5 patients had anti-cM1/D1a IgG antibodies. Monoclonal
antibodies detected both GM1 and GD1a epitopes on the LOSs of the C. jejuni isolates obtained
from the 5 patients. All the 5 isolates had class A LOS biosynthesis locus and cstII encoding the
mono-functional CstII (Thr51) variant, both of which are associated with the biosynthesis of
GM1-like and GD1a-like LOSs [20]. Although these genotypic results suggested GM1 and
GD1a mimicry, structural analysis was required to rule out the presence of a GM1b epitope
that could have triggered the anti-GM1b antibody production in these patients.
Table 1. IgG antibody titers in Guillain-Barré syndrome patients fromwhomC. jejuniwas isolated and who had anti-GM1/GD1a complex antibod-
ies, but neither anti-GM1 nor anti-GD1a antibodies.
IgG antibodies to (titer)
Patient Age/Sex Isolated ganglioside a Ganglioside- complex b
1 24/M GM1b (32,000) GM1/GD1a (16,000)
GM1/GT1b (4,000)
GD1a/GD1b (500)
2 81/F GM1b (16,000) GM1/GD1a (500)
3 26/M GM1b (32,000) GM1/GD1a (1,000)
4 16/F GM1b (128,000) GM1/GD1a (8,000)
GM1/GT1b (4,000)
GD1a/GD1b (1,000)
5 13/M GM1b (64,000) GM1/GD1a (2,000)
GD1b (2,000) GM1/GT1b (1,000)
GD1a/GD1b (1,000)
aTested antigens were GM1, GM1b, GM2, GD1a, GalNAc-GD1a, GD1b, GD2, GT1a, GT1b, and GQ1b gangliosides.
bTested antigens were GM1/GD1a, GM1/GD1b, GM1/GT1b, GD1a/GD1b, GD1a/GT1b, and GD1b/GT1b complexes.
doi:10.1371/journal.pone.0124004.t001
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Capillary electrophoresis coupled to electrospray ionization mass spectrometry (CE-ESI-MS)
was performed to analyze O-deacylated samples and to propose the LOS outer core structures
for the 2 isolates (GC016 and GC105) from Patients 1 and 3, respectively. The CE-ESI-MS data
showed mass species with either 1 or 2 sialic acids (S1 Table), which are proposed to be derived
from GM1 and GD1a mimicry (Fig 1B). The glycosyltransferase variants in the LOS biosynthe-
sis locus of GC016 and GC105 are consistent with GM1/GD1a mimicry with a mono-functional
CstII (Thr51) that will transfer a single sialic acid to the galactose residues. GM1b mimicry was
ruled out because the CgtA (β-1,4-N-acetylgalactosaminyltransferase) and CgtB (β-1,3-galacto-
syltransferase) variants are specific to sialylated acceptors, which implies that the inner galactose
residue must be substituted with a sialic acid. Based on the relative abundance of the quadruply
charged ions for each mass species (data not shown), we estimated that the ratio of GM1:GD1a
mimics was 1:3 for GC016, whereas it was estimated to be 3:1 for GC105.
GM1-like and GD1a-like LOSs of C. jejuni (GC016) were treated with the A. ureafaciens
neuraminidase. The treatment resulted in a decrease of the anti-GD1a antibody binding to the
LOS and an increase of the anti-GM1 antibody binding (Fig 1C), indicating that GD1a-like
LOS was converted to GM1-like LOS. cM1/D1a serum (S382) IgG antibodies were absorbed by
cM1/D1a and GM1/GD1a-like LOS, but not by the neuraminidase-treated GC016 LOS or
GM1/GM2-like LOS (Fig 1D). In contrast, the GM1b-specific serum (S8056) bound to the
GM1/GD1a-like LOS, but not to the GM1-like LOS alone, when tested by enzyme-linked im-
munosorbent assay and thin-layer chromatography-immunostaining (data not shown). These
data suggest that complex formation of GM1-like and GD1a-like LOSs could induce the pro-
duction of anti-GM1b antibodies in such patients.
Induction of anti-GM1b antibodies in mice
Sensitization of immune-naive mice with C. jejuni (GC105) bearing GM1-like and GD1a-like
LOSs induced the production of high titers (OD>1.0) of anti-GM1b antibodies in 4 of 13
mice, as well as anti-GM1 antibodies in 10 mice and anti-GD1a antibodies in 9 mice. In con-
trast, immunization with C. jejuni (NCTC11168) bearing GM1-like and GM2-like LOSs did
not induce the production of anti-GM1b antibodies in any of the 8 mice tested, and resulted in
the induction of anti-GM1 antibodies in 7 mice and anti-GD1a antibodies in 5 mice.
Cross-reactive antibodies to cM1/D1a with GM1b
Anti-cM1/D1a IgG antibodies were found in 20 of the 119 patients with neuropathy and its re-
lated conditions from whom C. jejuni had been isolated, whereas no anti-cM1/D1a antibodies
were detected in the sera from 105 healthy subjects and 83 patients with other neurological dis-
orders such as amyotrophic lateral sclerosis and myasthenia gravis. Five of the 20 patients car-
ried anti-cM1/D1a IgG antibodies (1:500 to 1:16,000), but neither anti-GM1 nor anti-GD1a
IgG antibodies (Table 1). All the 5 patients had GBS, but not Miller Fisher syndrome. Surpris-
ingly, all of the 5 patients carrying anti-cM1/D1a antibodies had high titers of anti-GM1b IgG
antibodies (1:16,000 to 1:128,000). Fig 2A demonstrates that IgG antibodies from Patient 4 in
Table 1 reacted with GM1b and cM1/D1a, but with neither GM1 nor GD1a.
Anti-cM1/D1a IgG antibodies from the patients were dose-dependently absorbed by GM1b,
as well as by cM1/D1a, but by neither GM1 nor GD1a, indicating that anti-cM1/D1a antibodies
cross-react with GM1b. Fig 2B shows representative results using serum from a patient with
GBS after C. jejuni enteritis (S6325). Anti-GM1b antibodies also were absorbed by cM1/D1a,
as well as by GM1b, but by neither GM1 nor GD1a.
Campylobacter LOS Complex in GBS
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Anti-GM1b antibodies and C. jejuni LOSs
Based on the ganglioside-mimicking pattern of C. jejuni LOSs, the 119 neuropathic patients
were classified into three groups; (i) both GM1 and GD1a mimics, (ii) GM1 mimic alone, and
(iii) neither GM1 nor GD1a mimic (Table 2). The first group of patients more often had IgG
antibodies to GM1 and GD1a, as well as to cM1/D1a, than the others, and each difference was
statistically significant. The autoantibody response was dependent on individuals: For exam-
ple, some patients infected by C. jejuni bearing GM1 and GD1a epitopes showed specific anti-
GM1 antibodies elevation (35%), and others carried both anti-GM1 and -GD1a antibodies,
with no anti-cM1/D1a activity (28%). Expectedly, the neuropathic patients infected by
C. jejuni carrying GM1 and GD1a epitopes had IgG autoantibodies to GM1b more frequently
than the others.
Fig 2. Complex of GM1 and GD1a (cM1/GD1a). (A) Immunostaining with IgG antibodies from Patient 4.
Bovine brain ganglioside mixture (lane 1), authentic GM1b (lane 2) and a mixture of GM1 and GD1a (lane 3)
were spotted on a thin-layer chromatogram plate and developed with a solvent. After the development of the
plate, a mixture of GM1 and GD1a was spotted and not further resolved (lane 4). The patient’s IgG strongly
bound to GM1b (asterisk) with the development, and to the mixture of GM1 and GD1a that was not separated
(arrow). In contrast, the binding nearly disappeared after separation of GM1 and GD1a with the development
(arrow head). (B) Cross-reactivity of the antibodies to cM1/D1a with GM1b. IgG anti-cM1/D1a antibodies of
serum (S6325) from a patient with GBS subsequent to C. jejuni enteritis were dose-dependently absorbed by
GM1b, as well as by cM1/D1a, whereas the antibodies were absorbed by neither GM1 nor GD1a.
doi:10.1371/journal.pone.0124004.g002
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Discussion
In the current study, C. jejuni strains expressing GM1 and GD1a mimics, but not GM1b mim-
ics, were isolated from GBS patients who harbored anti-GM1b antibodies. More importantly,
one of the strains (GC105) could induce the development of anti-GM1b antibodies in mice. In
a comprehensive study, 5 of 26 C. jejuni strains from GBS and Miller Fisher syndrome express-
ed GM1b mimics [21]. Anti-ganglioside antibody results were not available in that study, but
the presence of a GM1b mimic in a C. jejuni strain would provide a straightforward mechanism
to explain an anti-GM1b antibody response. In the same study, 8 of the strains isolated from
GBS patients expressed GM1 and GD1a mimics. Since two authors (J.L. and M.G.) were in-
volved in the structural characterization in both studies, the same analytical methods were ap-
plied to make sure we did not overlook the possible presence of GM1b mimics in the strains
from the current study.
All the GBS patients who carried the anti-cM1/D1a antibodies harbored anti-GM1b anti-
bodies, and 5 of them had neither anti-GM1 nor anti-GD1a antibodies. The anti-cM1/D1a an-
tibodies were absorbed by GM1b, and the anti-GM1b antibodies were absorbed by cM1/D1a,
suggesting that cM1/D1a forms a GM1b epitope. This was supported by the induction of the
anti-GM1b antibodies in mice immunized with a C. jejuni strain (GC105) bearing both
GM1-like and GD1a-like LOSs. Two-thirds of the patients with neuropathy from whom
C. jejuni strains bearing GM1 and GD1a epitopes were isolated had the anti-GM1b antibodies
(Table 2). In one study, a C. jejuni strain was shown to have LOS mimicking GM1 and GD1a,
and the patient with GBS from whom the strain was isolated had higher titer (1:12,800) of anti-
cM1/D1a IgG antibodies, lower titer (1:800) of anti-GM1 IgG antibodies and no anti-GD1a an-
tibodies [8]. The anti-GM1b antibody result was not available, but this patient might have had
anti-GM1b antibodies, based on the high titer of anti-cM1/D1a antibodies.
In the current study, immunization with C. jejuni bearing GM1-like and GD1a-like LOSs
induced the development of anti-GM1b antibodies in some mice, and anti-GM1 or anti-
GD1a antibodies in others. In an earlier study, similarly, some patients with GBS carried
anti-GM1b and anti-GM1 antibodies, whereas others carried either only anti-GM1 or anti-
GM1b antibodies [22].
In conclusion, GM1-like and GD1a-like LOSs may form a GM1b epitope, inducing the de-
velopment of anti-GM1b antibodies. The exact structural basis for the presentation of a GM1b
epitope does not seem to rely on the relative proportions of GM1-like and GD1a-like in the
LOS, since we observed very different ratios of GM1:GD1a mimics (3:1 vs 1:3) in the two
Table 2. IgG antibodies to GM1, GD1a, GM1/GD1a complex and GM1b in neuropathic patients fromwhomCampylobacter jejuniwas isolated.
IgG antibodies to
Ganglioside mimics of C. jejuni isolates GM1/GD1a
n GM1 GD1a complex GM1b
Both GM1 and GD1a 57 42 (74%)a 25 (44%)b 14 (25%)c 36 (63%)d
Only GM1 11 7 (64%) 4 (36%) 1 (9%) 6 (55%)
Neither GM1 nor GD1a 51 11 (22%) 8 (16%) 5 (10%) 13 (25%)
Patients are subgrouped based on ganglioside mimics on the lipo-oligosaccharide of their C. jejuni isolate. Signiﬁcant increase compared to other patients
ap <0.001, odds ratio [OR] = 6.8, 95% conﬁdence interval [CI] = 3.1–15.3;
bp = 0.005, OR = 3.3, 95% CI = 1.4–7.4;
cp = 0.048, OR = 3.0, 95% CI = 1.1–8.6;
d p <0.001, OR = 3.9, 95% CI = 1.8–8.3.
doi:10.1371/journal.pone.0124004.t002
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strains that were analyzed by mass spectrometry. In this study, we have presented a new para-
digm, demonstrating that the complex of two different structures form a new molecular mim-
icry, inducing the production of autoantibodies.
GM1 and GD1a are strongly expressed in the human peripheral nerves, whereas GM1b is
weakly expressed in these tissues [3]. GM1 and GD1a form a heteromeric complex in murine
peripheral nerves [23]. Along with our findings, both GM1b and cM1/D1a may be targets of
anti-GM1b and anti-cM1/D1a antibodies in the peripheral nerves. Infection by C. jejuni bear-
ing GM1 and GD1a epitopes may induce the production of anti-GM1b antibodies, which bind
to GM1b itself or to a heteromeric complex of GM1 and GD1a at the nodes of Ranvier and acti-
vate complement in the peripheral motor nerves. As shown in a rabbit model of axonal GBS
[24], the autoimmune attack should result in the disappearance of voltage-gated sodium chan-
nel clusters and disruption of the paranodal junctions, leading to motor nerve conduction fail-
ure and muscle weakness in patients with GBS.
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